title: Tumoral markers (CA 125--CEA) in the screening of ovarian cancer.
abstract: Ovarian cancer has high rate of mortality among malignant gynecologic tumors. Because of its aggressiveness and low rate of 5 year survival of patients treated, it is important to realise a screening program for its early diagnosis. Today, immunologic research is directed to the study of tumoral markers that allow us to detect the presence of still clinically silent ovarian neoplasms. Some tumoral markers such as CEA and CA 125 are available for post-surgical monitoring of patients treated for ovarian cancer. The Authors have carried out a study to evaluate the possibility of their use in the depistage of ovarian neoplastic pathology. A blood sample was taken for the evaluation of serum CEA and CA 125 in a series of 520 patients older than 45 years, who did not complain signs or symptoms of pelvic pathology. A pathologic value for CEA was considered higher than 7.3 ng/ml and for CA 125 greater than 37 U/ml. For CEA 2.5% (13 cases) presented pathologic values compared to 2.88% (15 cases) for CA 125. One third of cases (0.5%) with high levels of CEA had repeated blood samples. 3 of them had confirmed high levels of CEA but echotomography performed in these patients was negative for pathologic ovarian masses. 15 patients had CA 125 high levels. 3 out of 15 cases repeated the blood sample that resulted normal. On 11 of these cases an echotomography was also performed that diagnosed a uterine myomatosis in 4 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Obstetrics and Gynecology Department, Institute for Chilhood, Trieste, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Alberico
authors.forename: M C
authors.initials: MC
authors.lastname: Facca
authors.forename: R
authors.initials: R
authors.lastname: Millo
authors.forename: L
authors.initials: L
authors.lastname: Radillo
authors.forename: G P
authors.initials: GP
authors.lastname: Mandruzzato
mesh_terms: D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D003362:Cost-Benefit Analysis; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000517:prevention & control*; D012307:Risk Factors
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen